VerifyNow PRU(P2Y12) Test

Order Name: PRU(P2Y12) Test Test Number: 1570353 Revision Date: 08/30/2019

TEST NAME			METHODOLOGY	LOINC CODE
VerifyNow PRU(P2Y12) Test		Turbidometric Optical Platelet Aggregation	53813-2	
SPECIMEN REQUIR	EMENTS			
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	2 mL	Whole Blood	Greiner Bio-One 3.2% Na-Citrate	e Room Temperature
Instructions	 [1] Use 2 ml Greiner Bio-One partial-fill vacuette tubes with 3.2% sodium citrate (blue top). [2] Collect 3 tubes of whole blood using a 21 gauge or larger needle. First, draw a separate sodium citrate (blue top) tube (at least 2 mL) making sure the tube does not contain any platelet inhibiting substance (e.g. EDTA). Discard this tube. [3] Fill each Greiner partial-fill sample tube to the black line (1/2 tube). Do not under fill. [4] If drawing blood for a CBC at the same time, fill the CBC tube last. [5] Gently invert the tubes at least 5 times to ensure complete mixing of the contents. Samples with evidence of clotting should not be used. [6] Label the tubes with the patient ID, date and time it was drawn. Do not refrigerate or continue to rotate or agitate the tube. Testing is performed on blood collected in a 2 mL Greiner Bio-One partial fill sodium citrate tube with 3.2% sodium citrate which cannot be refrigerated or sent to the laboratory via pneumatic tube system. Testing is ideally performed within 4 hours of specimen collection. Patients should not be tested within 48 hours of the administration of eptifibatide (<i>Integrilin</i>) or tirofiban (<i>Aggrastat</i>) or 14 days following the administration of abciximab (<i>ReoPro</i>). Testing will be available for St. John Medical Center for in-patients and for patients sent from physician offices for testing. Because of the special testing requirements, outpatients should present to the 5th floor draw site in the Siegfried Tower at 1923 S Utica, Monday through Friday, 8 AM - 8 PM, for specimen collection. Please contact Brent Hartsell, MD, Kendra Thompson, or David Belanger at 918.744.2500 at x15529 or x16254 should you have any questions. 			
GENERAL INFORM	ATION			
Testing Schedule		Reach Patient See Instructions)	
Expected TAT	Within 4 hours of set up			
Clinical Use	The VerifyNow PRU Test is designed to measure P2Y12 receptor blockade. Results of the PRU Tests are reported as P2Y12 Reaction Units (PRU). PRU measures the extent of platelet aggregation in the presence of a P2Y12 inhibitor Lower PRU levels are associated with expected antiplatelet effect. <180 PRU – suggests P2Y12 inhibitor effect 180-376 PRU – suggests lack of P2Y12 inhibitor effect			
CPT Code(s)	85576			
Lab Section	Coagulation			